Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
WIGRETTES vs ERGOSTAT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nicotine replacement therapy: binds to nicotinic acetylcholine receptors in the brain, releasing dopamine and providing nicotine to reduce withdrawal symptoms and cravings.
Ergostat (ergotamine) is a serotonin (5-HT) receptor agonist, specifically at 5-HT1B and 5-HT1D receptors, leading to cranial vasoconstriction and inhibition of neurogenic inflammation. It also has partial agonist/antagonist activity at alpha-adrenergic receptors.
Smoking cessation therapy,Relief of nicotine withdrawal symptoms
FDA-approved: Acute treatment of migraine headache with or without aura,Off-label: Cluster headache, vascular headache
1 mg sublingually as needed for smoking cessation, up to 4 times daily. Maximum daily dose: 4 mg.
0.2 mg intramuscularly or intravenously every 2-4 hours for maximum 5 doses; not to exceed 1 mg total dose.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in moderate renal impairment.
Terminal half-life is 2–3 hours (intravenous) and 2–4 hours (oral). Short half-life necessitates frequent dosing; duration of action limited to 2–4 hours.
Primarily hepatic via CYP2A6 and CYP2B6; also metabolized by aldehyde oxidase and N-glucuronidation.
Primarily hepatic via CYP3A4. Undergoes extensive first-pass metabolism.
Renal excretion of unchanged drug accounts for 50-60% of the dose; biliary/fecal elimination accounts for 20-30%; remainder metabolized.
Primarily hepatic (biliary-fecal) elimination: ~90% of a dose is excreted in feces as metabolites; renal excretion accounts for <5% unchanged drug.
90-95% bound to albumin and alpha-1-acid glycoprotein.
~65% bound to plasma albumin. Metabolites are less extensively bound.
Volume of distribution is 0.8-1.2 L/kg, indicating extensive tissue distribution.
Approximately 0.2–0.3 L/kg, indicating primarily extracellular and peripheral tissue distribution with limited CNS penetration.
Oral bioavailability is 60-80%; intramuscular bioavailability is 90-100%.
Oral: ~10–20% (extensive first-pass metabolism); Sublingual: ~50–60% (avoids portal circulation); Rectal: ~30–40% (variable).
No specific dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
No specific adjustment; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 1 mg maximum twice daily. Child-Pugh Class C: Avoid use (not recommended).
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Not approved for patients under 18 years of age.
Intravenous: 0.1 mg/m² body surface area every 2-4 hours, maximum 0.5 mg total; intramuscular: 0.2 mg every 2-4 hours, maximum 1 mg.
No specific dose adjustment; monitor for adverse effects due to potential age-related decreased renal function.
Start at 0.1 mg intramuscularly or intravenously; monitor for hypertension with higher doses.
None
Concomitant use with strong CYP3A4 inhibitors (e.g., protease inhibitors, macrolide antibiotics, azole antifungals) can lead to serious and/or life-threatening peripheral ischemia and vasospasm. Avoid coadministration.
Risk of nicotine toxicity if used while smoking; caution in cardiovascular disease, hypertension, diabetes, hyperthyroidism, pheochromocytoma; may cause allergic reactions including angioedema; pregnancy category D.
Risk of ischemia (peripheral, cerebral, coronary) especially with prolonged use or overdose,Fibrotic complications (cardiac valvulopathy, pulmonary, retroperitoneal fibrosis) with chronic use,Medication overuse headache (MOH) with frequent use, Avoid in patients with uncontrolled hypertension, coronary artery disease, or peripheral vascular disease,Do not exceed recommended dosage; may cause ergotism
Hypersensitivity to nicotine or any component; nonsmokers; immediate post-myocardial infarction period; life-threatening arrhythmias; severe or worsening angina pectoris.
Concurrent use of potent CYP3A4 inhibitors (e.g., boceprevir, clarithromycin, ketoconazole, ritonavir)
No known food interactions. Avoid concurrent use of retinoid creams or other exfoliating agents that may increase skin sensitivity.
Avoid grapefruit juice as it may increase ergonovine levels. No other significant food interactions.
WIGRETTES contains nicotine, which is a known teratogen. First trimester exposure is associated with increased risk of spontaneous abortion, preterm birth, and low birth weight. Second and third trimester exposure can lead to reduced fetal growth, placental complications (e.g., abruption), and potential neurobehavioral effects. The risk is dose-dependent and compounded by maternal smoking.
Ergostat (ergonovine) is contraindicated in pregnancy due to its potent uterotonic effects, which can cause uterine tetany, fetal hypoxia, and placental abruption. It is classified as FDA Pregnancy Category X. Use in the first trimester may increase the risk of spontaneous abortion; in the second and third trimesters, it can precipitate preterm labor and fetal distress. There is no evidence of structural teratogenicity from direct drug effects, but the potential for ischemic injury to the fetus due to uterine hyperstimulation exists.
Nicotine is excreted into breast milk with a milk-to-plasma ratio of approximately 2.9. Concentrations can exceed maternal serum levels. Nursing infants are at risk for nicotine absorption leading to irritability, sleep disturbances, and reduced milk intake. Breastfeeding is generally discouraged during nicotine replacement therapy; if used, timing of patches should minimize infant exposure (e.g., remove at night).
Ergonovine is excreted into breast milk. The M/P ratio is not well established, but small amounts are detectable. It may cause adverse effects in the nursing infant, including vomiting, diarrhea, and transient hypertension. Because of the risk of ergotism in the infant, breastfeeding is generally not recommended during therapy. A decision should be made to discontinue breastfeeding or discontinue the drug, considering the importance of the drug to the mother.
Pregnancy increases nicotine clearance by approximately 60%, potentially reducing efficacy of standard doses. Higher doses of nicotine replacement therapy may be required to achieve therapeutic effect and prevent withdrawal. However, safety of high-dose NRT in pregnancy is not established. Dose should be individualized based on maternal smoking history and withdrawal symptoms.
No dosing adjustments are recommended or studied because use in pregnancy is contraindicated. If exposure occurs accidentally or for life-threatening indications (e.g., severe postpartum hemorrhage), the same doses used in non-pregnant adults (0.2 mg IM or IV) may be employed, but with extreme caution due to heightened sensitivity to uterotonic effects. No pharmacokinetic studies in pregnancy exist; however, increased plasma volume and altered hepatic metabolism may require careful titration, but no specific evidence supports dose changes.
Wigrettes are wax-based hair removal products containing depilatory agents like calcium thioglycolate. For scalp use only; avoid contact with eyes and broken skin. Perform a patch test 24 hours prior to first use. Do not use on irritated or sunburned skin. Overuse may cause chemical burns or allergic contact dermatitis. Duration of application time is critical: typically 5-10 minutes, do not exceed 15 minutes. Remove with a wooden spatula in direction of hair growth. Neutralize residue with water or mild soap.
ERGOSTAT (ergonovine) is an ergot alkaloid used for postpartum hemorrhage. It causes sustained uterine contraction. Contraindicated in hypertension, preeclampsia, and vascular disease. Administer IM or IV slowly over 1 minute to avoid severe vasoconstriction. Monitor blood pressure and uterine tone closely. Do not use in patients with hypersensitivity to ergot alkaloids.
Read all directions before use.,Do a patch test on a small area of skin 24 hours before use.,Apply only to clean, dry scalp hair; not for eyebrows, eyelashes, or body hair.,Avoid contact with eyes, nose, and mouth. If contact occurs, rinse with plenty of water.,Do not use on sunburned, broken, or irritated skin.,Set a timer; do not leave on longer than directed (usually 5-10 minutes, max 15 minutes).,Remove product gently with the provided spatula in the direction of hair growth.,Rinse scalp thoroughly with water after removal; do not use soap immediately if irritation occurs.,Do not use more than once every 72 hours.,Store in a cool, dry place away from children.
This medication is given to control bleeding after childbirth.,It may cause nausea, vomiting, or dizziness.,Report severe headache, chest pain, or vision changes immediately.,Avoid smoking or using nicotine products while on this drug.,Do not breastfeed within 12 hours after the last dose; discuss with your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about WIGRETTES vs ERGOSTAT, answered by our medical review team.
WIGRETTES is a Ergot Alkaloid that works by Nicotine replacement therapy: binds to nicotinic acetylcholine receptors in the brain, releasing dopamine and providing nicotine to reduce withdrawal symptoms and cravings.. ERGOSTAT is a Ergot Alkaloid Antimigraine that works by Ergostat (ergotamine) is a serotonin (5-HT) receptor agonist, specifically at 5-HT1B and 5-HT1D receptors, leading to cranial vasoconstriction and inhibition of neurogenic inflammation. It also has partial agonist/antagonist activity at alpha-adrenergic receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between WIGRETTES and ERGOSTAT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of WIGRETTES is: 1 mg sublingually as needed for smoking cessation, up to 4 times daily. Maximum daily dose: 4 mg.. The standard adult dose of ERGOSTAT is: 0.2 mg intramuscularly or intravenously every 2-4 hours for maximum 5 doses; not to exceed 1 mg total dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between WIGRETTES and ERGOSTAT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. WIGRETTES is classified as Category C. WIGRETTES contains nicotine, which is a known teratogen. First trimester exposure is associated with increased risk of spontaneous abortion, preterm birth, and low birth weight. Se. ERGOSTAT is classified as Category C. Ergostat (ergonovine) is contraindicated in pregnancy due to its potent uterotonic effects, which can cause uterine tetany, fetal hypoxia, and placental abruption. It is classified. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.